netFormulary
 Report : Medicines with links to NICE 17/08/2018 07:10:47

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abiraterone 08.03.04.02 Non Formulary NICE TA259: Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
Acenocoumarol 02.08.02 Formulary NICE CG144: Venous thromboembolic diseases
Acenocoumarol 02.08.02 Formulary NICE CG144: Venous Thromboembolism
Adalimumab 01.05.03 Restricted Use NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
Adalimumab 01.05.03 Restricted Use NICE TA187: Crohns disease - infliximab (review) and adalimumab (review of TA40)
Adalimumab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Adalimumab 13.05.03 Formulary NICE (2008) Adalimumab for the treatment of adults with psoriasis. (TA146).
Adefovir Dipivoxil 05.03.03.01 Formulary NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
Adefovir Dipivoxil 05.03.03.01 Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA96
Aflibercept 11.08.02 Formulary NICE TA294: Aflibercept for treating wet age-related macular degeneration
Aflibercept 11.08.02 Formulary NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA346: Aflibercept for treating diabetic macular oedema
Aflibercept 11.08.02 Formulary NICE TA486: Aflibercept for treating choroidal neovascularisation
Alemtuzumab 08.02.03 Formulary NICE TA312: Alemtuzumab for treating relapsing-remitting multiple sclerosis
Alirocumab 02.12 Formulary NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Restricted Use NICE TA177: Eczema (chronic) - alitretinoin
Alteplase 02.10.02 Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TA156: Anti-D in pregnant women
Apixaban 02.08.02 Formulary NICE TA341: Apixaban for the treatment and secondary prevention of DVT/PE
Apixaban 02.08.02 Formulary NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)
Apremilast 10.01.03 Formulary NICE TA433: Apremilast for treating active psoriatic arthritis
Aripiprazole 04.02.01 Formulary NICE TA292: Aripiprazole for manic episodes in adolescents with bipolar I disorder
Aripiprazole 04.02.01 Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years
Azacitadine SC Injection 24.03 Formulary NICE TA399: Azacitidine for treating acute myeloid leukaemia
Azacitidine 08.01.03 Formulary NICE TA218: azacitidine for myelodysplastic syndromes
Baricitinib 10.01.03 Formulary NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
Bee and Wasp Allergen Extracts 03.04.02 Formulary NICE TA246: Pharmalgen for the treatment of bee and wasp venom allergy
Bendamustine 08.01.01 Formulary NICE TA216: Bendamustine for CLL
Bevacizumab 08.01.05 Formulary NICE TA263: Breast cancer with capecitabine
Bevacizumab 08.01.05 Formulary NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Bevacizumab 08.01.05 Formulary NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Formulary NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bivalirudin 02.08.01 Non Formulary NICE TA230: Bivalirudin for the treatment of STEMI, 2011
Bivalirudin 02.08.01 Non Formulary NICE CG94: Unstable angina and NSTEMI
Boceprevir 05.03.03.02 Non Formulary NICE TA253: Boceprevir for the treatment of genotype 1 chronic hepatitis C
Bortezomib 08.01.05 Formulary NICE TA129: Multiple myeloma - bortezomib
Bortezomib 08.01.05 Formulary NICE TA228:Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Botulinum Toxin Type A 04.07.04.02 Non Formulary NICE TA260: Botox for migraine prophylaxis
Brentuximab IV Infusion 24.03 Formulary NICE Technology Appraisals
Cabazitaxel 08.01.05 Non Formulary NICE TA255: Cabazitaxel for prostate cancer
Calcipotriol 13.05.02 Restricted Use NICE CG153: Psoriasis
Canagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
Capecitabine 08.01.03 Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Capecitabine 08.01.03 Formulary NICE TA60: Colorectal cancer - capecitabine and tegafur uracil
Capecitabine 08.01.03 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Capsaicin 10.03.02 Formulary NICE CG177: Osteoarthritis
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Certolizumab Pegol 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Certolizumab Pegol 10.01.03 Formulary NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Cetuximab 08.01.05 Non Formulary NICE TA172: Head and neck cancer (squamous cell carcinoma) - cetuximab
Cetuximab 08.01.05 Non Formulary NICE TA145: Head and neck cancer - cetuximab
Cetuximab 08.01.05 Non Formulary NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
Cetuximab 08.01.05 Non Formulary NICE TA176: Colorectal cancer (first line) - cetuximab
Cinacalcet 09.05.01.02 Formulary NICE TA117: Hyperparathyroidism - cinacalcet
Clopidogrel 02.09 Formulary NICE TA210: Clopidogrel/dipyridamole MR prevention of occlusive vascular events.
Colistimethate inhaler 05.01.07 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)
Crizotinib 08.01.05 Non Formulary NICE TA296: Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene
Dabigatran 02.08.02 Formulary NICE TA157: Dabigatran for prophylaxis of VTE post hip or knee surgery
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran for Stroke prevention in AF
Dabigatran 02.08.02 Formulary NICE TA327: Dabigatran for the treatment and secondary prevention of DVT/PE
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Dasatinib 08.01.05 Formulary NICE TA241: CML for whom treatment with imatinib has failed because of intolerance
Decitabine 08.01.03 Non Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270)
Denosumab 06.06.02 Formulary NICE TA265: Bone metastases from solid tumours - denosumab: guidance (TA265 )
Denosumab 06.06.02 Formulary NICE TA204: Osteoporotic fractures - denosumab
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema
Diltiazem Cream 2% 01.07.04 Formulary NICE evidence summary
Dimethyl fumarate 13.05.02 Restricted Use NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
Dipyridamole 02.09 Formulary NICE TA 210: Clopidogrel/dipyridamole MR for prevention of occlusive vascular events
Dipyridamole and Aspirin 02.09 Formulary NICE TA210: Clopidogrel/dipyridamole MR for prevention of occlusive vascular events.
Docetaxel 08.01.05 Non Formulary NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Docetaxel 08.01.05 Non Formulary NICE TA109: Breast cancer (early) - docetaxel
Doxorubicin Hydrochloride 08.01.02 Formulary NICE TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review)
Dronedarone 02.03.02 Restricted Use NICE TA197: Atrial fibrillation - dronedarone
Edoxaban 02.08.02 Formulary NICE TA355: Edoxaban for stroke prevention in AF
Edoxaban 02.08.02 Formulary NICE TA354: Edoxaban for treating and preventing DVT/PE
Elbasvir/Grazoprevir 05.03.03.02 Formulary NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
Eltrombopag 09.01.04 Formulary NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205)
Empagliflozin 06.01.02.03 Formulary NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
Empagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Entecavir 05.03.03.01 Formulary NICE CG165: Hepatitis B (incorporates TA153)
Entecavir 05.03.03.01 Formulary NICE TA153: Hepatitis B (chronic) - etecavir
Eplerenone 02.02.03 Formulary NICE CG172 MI – secondary prevention: Secondary prevention in primary and secondary care for patients following a myocardial infarction
Eribulin 08.01.05 Non Formulary NICE TA250: Breast cancer (advanced) - eribulin (TA250)
Erlotinib 08.01.05 Non Formulary NICE TA162: Lung cancer (non-small-cell) 2nd line- erlotinib
Etanercept 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Etanercept 10.01.03 Formulary NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Etanercept 10.01.03 Formulary NICE TA35: Arthritis (juvenile idiopathic) - etanercept
Etanercept 13.05.03 Formulary NICE TA103: Psoriasis - efalizumab and etanercept
Everolimus 08.01.05 Non Formulary NICE TA294: Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor):
Everolimus 08.01.05 Non Formulary NICE TA219: Everolimus for second-line treatment of renal cell cancer
Evolocumab 02.12 Formulary NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exenatide Prolonged Release 06.01.02.03 Formulary NICE TA248: Exenatide Prolonged Release
Ezetimibe 02.12 Formulary NICE TA132: Hypercholesterolaemia - ezetimibe
Febuxostat 10.01.04 Formulary NICE TA164: Febuxostat for the management of hyperuricaemia in people with gout
Finasteride 06.04.02 Formulary NICE CG97: Lower urinary tract symptoms: quick reference guide
Fingolimod 08.02.04 Non Formulary NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 08.01.03 Formulary NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fludrocortisone Acetate 06.03.01 Formulary NICE Evidence Summary: Postural Hypotension in Adults
Fluocinolone intravitreal implant 11.04.01 Formulary NICE TA301: Diabetic macular oedema - fluocinolone acetonide intravitreal implant (TA271)
Fulvestrant 08.03.04.01 Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Gefitinib 08.01.05 Non Formulary NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Gemcitabine 08.01.03 Formulary NICE TA25: Pancreatic cancer - gemcitabine
Gemcitabine 08.01.03 Formulary NICE TA116: Breast cancer - gemcitabine
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Glucosamine 10.01.05 Non Formulary NICE CG177: ’Do not offer glucosamine or chondroitin products for the management of osteoarthritis’
Golimumab 10.01.03 Formulary NICE TA220: Psoriatic arthritis - golimumab
Golimumab 10.01.03 Formulary NICE TA233: Ankylosing spondylitis - golimumab
Golimumab 10.01.03 Formulary NICE TA225: Rheumatoid arthritis - golimumab
Imatinib 08.01.05 Formulary NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib
Imatinib 08.01.05 Formulary NICE TA70: Leukaemia (chronic myeloid) - imatinib
Imatinib 08.01.05 Formulary NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
Imatinib 08.01.05 Formulary NICE TA241: Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant): guidance
Imatinib 08.01.05 Formulary NICE TA196: Gastrointestinal stromal tumours - imatinib (adjuvant): guidance
Infliximab 01.05.03 Restricted Use NICE TA140: Ulcerative colitis (subacute manifestations) Infliximab
Infliximab 01.05.03 Restricted Use NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Restricted Use NICE TA187: Crohns disease - infliximab (review) and adalimumab (review of TA40)
Infliximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Infliximab 10.01.03 Formulary NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Infliximab 13.05.03 Formulary NICE TA134: Infliximab for psoriasis
Ipilimumab 08.01.05 Non Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ivabradine 02.06.03 Formulary NICE TA 267: Ivabradine
Labetalol 02.04 Formulary NICE CG107: Hypertension in Pregnancy
Lapatinib 08.01.05 Non Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Lenalidomide 08.02.04 Formulary NICE TA171: Lenalidomide for the treatment of multiple myeloma
Lenalidomide 08.02.04 Formulary NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Liraglutide 06.01.02.03 Formulary NICE TA203: Diabetes (type 2) - liraglutide
Lixisenatide 06.01.02.03 Formulary NICE ESNM26 Type 2 diabetes: lixisenatide May 2013
Magnesium Glycerophosphate 09.05.01.03 Non Formulary NICE: Evidence Summary: Magnesium glycerophosphate
Mannitol inhalation 03.07 Non Formulary NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation (TA266)
Methyldopa 02.05.02 Formulary NICE CG107: Hypertension in Pregnancy
Methylprednisolone 06.03.02 Formulary NICE CG186: Multiple Sclerosis; management in primary and secondary care.
MIDODRINE Tablets 2.5 mg, 5mg 20 Non Formulary NICE: Postural hypotension in adults: midodrine (ESUOM5)
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Modafinil 04.04 Formulary NICE Evidence Summary: Modafinil for fatigue in multiple sclerosis
Mycophenolate Mofetil 08.02.01 Formulary NICE TA481: Immunosuppressive therapy for renal transplantation in adults
Mycophenolate Mofetil 08.02.01 Formulary NICE TA99: Immunosuppressive therapy for renal transplantation in children and adolescents
Naltrexone 04.10.03 Restricted Use NICE TA115: Drug misuse - naltrexone
Natalizumab 08.02.04 Non Formulary NICE TA127: Multiple sclerosis - natalizumab
Nilotinib 08.01.05 Formulary NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Ocriplasmin 11.08.02 Non Formulary NICE TA297: Ocriplasmin for treating vitreomacular traction
Omalizumab 03.04.02 Restricted Use NICE TA278: asthma (severe, persistent, patients aged 6+, adults) - omalizumab
Omega-3-Acid Ethyl Esters 02.12 Formulary NICE CG181: Lipid Modification
Omega-3-Acid Ethyl Esters 02.12 Formulary NICE Evidence Summary: schizophrenia - omega-3 fatty acid medicines
Omega-3-Marine Triglycerides 02.12 Non Formulary NICE: schizophrenia - omega-3 fatty acid medicines
Oxaliplatin 08.01.05 Non Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Paclitaxel 08.01.05 Formulary NICE TA55: Ovarian cancer - paclitaxel (review)
Paclitaxel 08.01.05 Formulary NICE TA108: Breast cancer (early) - paclitaxel
Pazopanib 08.01.05 Non Formulary NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib
Peginterferon Alfa 05.03.03.01 Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA96
Peginterferon Alfa 05.03.03.01 Formulary NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
Peginterferon Alfa 05.03.03.02 Formulary NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa 05.03.03.02 Formulary NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Peginterferon Alfa 05.03.03.02 Formulary NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
Peginterferon Alfa 08.02.04 Formulary NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
Peginterferon Alfa 08.02.04 Formulary NICE TA 200: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Peginterferon Alfa 08.02.04 Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Pegloticase 20 Non Formulary NICE TA291: Pegloticase not recommended for severe chronic gout
Pemetrexed 08.01.03 Non Formulary NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Pemetrexed 08.01.03 Non Formulary NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed 08.01.03 Non Formulary NICE TA135: Mesothelioma - pemetrexed disodium
Pemetrexed 08.01.03 Non Formulary NICE TA124: Lung cancer (non-small-cell) - pemetrexed
Pimecrolimus 1% Cream 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
pirfenidone 03.11 Non Formulary NICE TA282: Idiopathic pulmonary fibrosis - pirfenidone (TA282)
Prasugrel 02.09 Formulary NICE TA317: Acute coronary syndrome - prasugrel
Prucalopride 01.06.07 Non Formulary NICE TA211: Constipation (women) Prucalopride
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE TA161:Osteoporosis - secondary prevention
Ranibizumab 11.08.02 Formulary NICE TA274: Ranibizumab for treating diabetic macular oedema
Ranibizumab 11.08.02 Formulary NICE TA298: Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
Ranibizumab 11.08.02 Formulary NICE TA283: Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
Ranibizumab 11.08.02 Formulary NICE TA155: Ranibizumab for the treatment of age-related macular degeneration
Retigabine 04.08.01 Formulary NICE TA232: Retigabine
Ribavirin 05.03.03.02 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 05.03.03.02 Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.03.02 Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Rifaximin 05.01.07 Formulary NICE TA337: rifaximin for preventing episodes of hepatic encephalopathy
Riluzole 04.09.03 Formulary NICE TA20: Motor neurone disease - riluzole
Rituximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Rituximab 08.02.03 Formulary NICE TA226: Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma
Rituximab 08.02.03 Formulary NICE TA65: Rituximab for aggressive non-Hodgkin’s lymphoma
Rituximab 08.02.03 Formulary NICE TA243:Rituximab for the first-line treatment of stage III-IV follicular lymphoma (January 2012)
Rituximab 08.02.03 Formulary NICE TA137: Lymphoma (follicular non-Hodgkins) - rituximab
Rituximab 08.02.03 Formulary NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab
Rituximab 08.02.03 Formulary NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab
Rituximab 08.02.03 Formulary NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rivaroxaban 02.08.02 Formulary NICE TA256: Rivaroxaban for AF
Rivaroxaban 02.08.02 Formulary NICE TA287: Rivaroxaban for treating PE and preventing recurrent venous thromboembolism
Rivaroxaban 02.08.02 Formulary NICE TA261: Rivaroxaban for treatment of DVT
Rivaroxaban 02.08.02 Formulary NICE TA170: Rivaroxaban for prevention of VTE post hip or knee surgery
Roflumilast 03.03.03 Formulary NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim 09.01.04 Formulary NICE TA221: Thrombocytopenic purpura - romiplostim
Sarilumab 10.01.03 Formulary NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 10.01.03 Formulary NICE TA445: Secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 13.05.03 Formulary NICE TA407: Secukinumab for active ankylosing spondylitis
Simeprevir 05.03.03.02 Formulary NICE TA331: Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C
Sofosbuvir 05.03.03.02 Formulary NICE TA330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir / Velpatasvir 05.03.03.02 Formulary NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
Sofosbuvir / Velpatasvir / Voxilaprevir 05.03.03.02 Formulary NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Somatropin 06.05.01 Non Formulary NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review)
Somatropin 06.05.01 Non Formulary NICE TA64: Growth hormone deficiency (adults) - human growth hormone
Sorafenib 08.01.05 Non Formulary NICE TA189: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)
Strontium Ranelate 06.06.02 Formulary NICE TA161: Osteoporosis - secondary prevention
Sunitinib 08.01.05 Non Formulary NICE TA179: Gastrointestinal stromal tumours - sunitinib
Sunitinib 08.01.05 Non Formulary NICE TA178: Renal cell carcinoma
Sunitinib 08.01.05 Non Formulary NICE TA169: Renal cell carcinoma - sunitinib
Tacrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tegafur with Uracil 08.01.03 Non Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telaprevir 05.03.03.02 Non Formulary NICE TA252:Telaprevir for the treatment of genotype 1 chronic hepatitis C
Temozolomide 08.01.05 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Temozolomide 08.01.05 Non Formulary NICE TA23: Brain cancer - temozolomide
Temsirolimus 08.01.05 Non Formulary NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
Temsirolimus 08.01.05 Non Formulary NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
Tenofovir and Emtricitabine 05.03.01 Formulary NICE Evidence Summary: Pre-exposure prophylaxis of HIV in adults at high risk: Truvada
Tenofovir Disoproxil 05.03.03.01 Formulary NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Tenofovir Disoproxil 05.03.03.01 Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA173
Tenofovir Disproxil 05.03.01 Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA173
Tenofovir Disproxil 05.03.01 Formulary NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Teriparatide 06.06.01 Formulary NICE TA161: Osteoporosis - secondary prevention
Thalidomide 08.02.04 Formulary NICE TA228: bortezomib and thalidomide for the first-line treatment of multiple myeloma.
Thiamine 09.06.02 Formulary NICE pathway: Acute alcohol withdrawal
Ticagrelor 02.09 Formulary NICE TA236: Ticagrelor for the treatment of acute coronary syndromes
Tobramycin 05.01.04 Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)
Tocilizumab 10.01.03 Formulary NICE TA198: Rheumatoid arthritis - tocilizumab
Tocilizumab 10.01.03 Formulary NICE TA518: Tocilizumab for treating giant cell arteritis
Tofacitinib 10.01.03 Formulary NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Topotecan 08.01.05 Non Formulary NICE TA91: Topotecan for ovarian cancer
Topotecan 08.01.05 Non Formulary NICE TA183: Cervical cancer (recurrent) - topotecan
Topotecan 08.01.05 Non Formulary NICE TA184: Lung cancer (small-cell) - topotecan
Trabectedin 08.01.05 Non Formulary NICE TA222- ovarian cancer
Trabectedin 08.01.05 Non Formulary NICE TA185: Soft tissue sarcoma - trabectedin
Trastuzumab 08.01.05 Non Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab 08.01.05 Non Formulary NICE TA34: Breast cancer - trastuzumab
Trastuzumab 08.01.05 Non Formulary NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Ustekinumab 13.05.03 Formulary NICE TA180: Psoriasis - ustekinumab
Ustekinumab 13.05.03 Formulary NICE (2015) Ustekinumab for treating active psoriatic arthritis (TA340)
Ustekinumab 10.01.03 Formulary NICE TA340: Ustekinumab for treating active psoriatic arthritis
Varenicline 04.10.02 Non Formulary NICE TA123: Varenicline
Vedolizumab 01.05.03 Restricted Use NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vedolizumab 01.05.03 Restricted Use NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vemurafenib 08.01.05 Non Formulary NICE TA176: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272)
Warfarin 02.08.02 Formulary NICE CG144: Venous Thromboembolism
The Pennine Acute Hospitals